Timing Targeted and Immunotherapies for Metastatic Melanoma

Source: Cancer Therapy Advisor, September 2017

Up to 15% of patients diagnosed with melanoma will develop metastatic tumors, against which chemotherapy is “largely ineffective,” with response rates as low as 5%.1,2 Approximately 45% of metastatic tumors harbor BRAFV600mutations that can be treated with targeted MAPK pathway inhibitors. The rapid response to these therapies translates into symptom relief, though acquired tumor resistance to BRAF and MEK inhibitors — usually through the reactivation of the ERK signaling pathway — is an ongoing clinical challenge.3-7

“I would not describe [resistance] as inevitable,” said Teresa Amaral, MD, of the Center for Dermatooncology at University Hospital Tubingen in Germany. “Results presented from a phase 2 trial evaluating the combination of dabrafenib plus trametinib showed that there are 12 patients still on treatment after 5 years.”8

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories